the aid library

LIST OPTIONS

Filter

443

Guidelines for Prevention and Control of Chikungunya Fever - 2009

World Health Organization - Regional Office for South-East Asia (2009) CC

This guideline for the prevention and control of chikungunya fever (CF) is intended for use by all peripheral health workers in the Region and is based on the strategy outlined above. This document will focus mainly on preventing, predicting and detecting outbreaks, and after detection, investig... more

External Link

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

Download (171)

View PDF (205)

Treatment of Leprosy

Lockwod DN. The International Textbook of Leprosy (2018) CC

This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is a key component of leprosy treatment, as it is vital to prevent the progression of the infection. Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with the ... more

External Link

Schistosomiasis: Still a Cause of Significant Morbidity and Mortality

Verjeen, M. National Library of Medicine (2019) CC

Theodor Bilharz, a German professor of anatomy and chief of surgery at the Kasr El Ani Hospital of Cairo from 1850, first identified an infective organism, Distomum hematobium in 1851, which was renamed Schistosoma haematobium in 1858. It arose from a cestode worm, Hymenoleptis nana, lying in the sm... more

External Link

Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system

Léger, E.; Borlase, A.; Fall, C. et al. The Lancet Planetary Health (2020) CC

Schistosomiasis is a neglected tropical disease of global medical and veterinary importance. As efforts to eliminate schistosomiasis as a public health problem and interrupt transmission gather momentum, the potential zoonotic risk posed by livestock Schistosoma species via viable hybridisation in s... more

External Link

Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda

Kuepfer, I.; Hhary, EP.; Mpairwe, A.; Edielu, A.; Burri, C.; Blum, JA. PLOS Neglected Tropical Diseases (2011) CC

A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d... more

External Link

Melarsoprol Resistance in African Trypanosomiasis

Fairlamb, A.H.; Horn, D. Elsevier Ltd. (2018) CC

Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT). Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s. Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher... more

External Link

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Suárez, C., Nolder, D., García-Mingo, A. et al. Research and reports in tropical medicine (2022) CC

Research and Reports in Tropical Medicine 2022:13 25–40. Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with po... more

Epidemiology of human African trypanosomiasis

Franco J, Simarro P, Diarra A, Jannin J (2014) CC

The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environment. Related to these interactions, the disease is confined in spatially limited areas called “foci�... more

External Link

Guide for the Medical, Veterinary and allied Professions

Bishop, G.; Durrheim, D.; Kloeck, P. et al. Department: Agriculture, Foresty and Fisheries - Republic of South Africa (2010) CC

Rabies is a disease of animals but too often the outcome is gauged in terms of human suffering and death. Despite this, in areas of the world where rabies is endemic there is often a lack of communication between veterinary and medical professionals, to the extent that the disease continues to thri... more

External Link

Laboratory techniques in rabies

Rupprecht, C.; Fooks, A,; Abela-Ridder, B. World Health Organization WHO (2018) C_WHO

Rabies has an enormous impact on both agriculture and conservation biology, but its greatest burden is undeniably on public health. As such, routine methods for rapid risk assessment after human exposures to rabies as well as applications for laboratory-based surveillance, production of biologicals ... more

External Link

Laboratory techniques in rabies Fifth edition Volume 2

Rupprecht, C.; Fooks, A.; Abela-Ridder, B. World Health Organization WHO (2019) C_WHO

WHO's Response to the Ukraine Crisis. Interim Report. February to June 2022

World Health Organization (WHO) (2022) C_WHO

The military offensive by the Russian Federation in Ukraine which began February 2022 has triggered one of the world’s fastest-growing displacement and humanitarian crisis, with geopolitical and economic ripples felt across the globe. The ongoing war has caused large-scale disruptions to the deliv... more

Préserver la Sécurité sanitaire et servir les populations vulnérables

World Health Organisation (WHO) (2023) C_WHO

Le 13ème programme général de travail (PGT) 2019-2023 de l’OMS va amorcer bientôt sa dernière année de mise en oeuvre. Cependant, le chemin vers l’objectif du « triple milliard » semble encore long, à savoir « faire en sorte qu’un milliard de personnes supplémentaires bénéficient ... more

WHO Ghana 2022 annual report
recommended

World Health Organisation (WHO) (2023) C_WHO

“2022 was an eventful year for the WHO Country Office in Ghana,” says Dr Francis Kasolo, WHO Representative to Ghana. In 2022, WHO Ghana collaborated with partners to deliver interventions in support of the Government of Ghana's health sector agenda to ensure healthy lives for all towards ach... more

Download (124)

View PDF (124)

The urgency of now - Turning the tide against epidemic and pandemic infectious diseases

Coalition for Epidemic Preparedness Innovations (CEPI) Coalition for Epidemic Preparedness Innovations (CEPI) (2021) CC

CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de... more

Download (195)

View PDF (337)

Global Strategic preparedness, readiness and response plan for Cholera
recommended

World Health Organisation (WHO) (2023) CC

Cholera is a major health risk in many parts of the world, affecting millions of people every year. Since mid-2021, the world has been facing an acute upsurge of the 7th cholera pandemic, which is characterized by the number, size and concurrence of multiple outbreaks, the spread to areas that had b... more

Download (246)

View PDF (193)

Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential

World Health Organization WHO (2023) C_WHO

Pathogen genomic surveillance has become a priority for public health systems in recent years. Genomic sequencing is increasingly being used to characterize pathogens and monitor important public health priorities (e.g. poliovirus, influenza virus, Mycobacterium tuberculosis and Vibrio cholerae, ant... more

Global report on children with developmental disabilities

World Health Organisation (WHO) (2023) C_WHO

Developmental disabilities are common. Yet, children with developmental disabilities have been neglected in health systems planning and policy provisions for health and continue to experience stigmatization, institutionalization, barriers to access health care and inequalities in health and educatio... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Ghana 2022 annual report recommended

Global Strategic preparedness, readiness and response plan for Cholera recommended

WHO Ghana 2022 annual report
recommended

Global Strategic preparedness, readiness and response plan for Cholera
recommended